Sutro, Sarepta, Incyte, Signet, Wix: Trending by Analysts

Analysts are intrested in these 5 stocks: ( (STRO) ), ( (SRPT) ), ( (INCY) ), ( (SIG) ) and ( (WIX) ). Here is a breakdown of their recent ratings and the rationale behind them.

Sutro Biopharma is gaining attention as analyst Edward Tenthoff from Piper Sandler upgraded the stock to Buy, highlighting its promising next-generation antibody-drug conjugates (ADCs). The company plans to file three investigational new drug applications over the next few years, including for STRO-004 and STRO-006, which have shown positive preclinical results. Sutro’s partnerships with Ipsen and Astellas, along with a strong cash position, bolster its potential. However, the company may require additional capital as it advances its pipeline.

Sarepta Therapeutics faces challenges as multiple analysts, including Kostas Biliouris and Biren Amin, downgraded the stock to Hold following a second patient death linked to its Elevidys treatment. The company has paused dosing in non-ambulatory patients and is working on an enhanced immunosuppressive regimen. Despite the setbacks, Sarepta’s expertise in Duchenne muscular dystrophy and its broader pipeline could provide future opportunities, though investor concerns remain high.

Incyte is on the rise with analyst Stephen Willey upgrading the stock to Buy, driven by promising data from its INCA033989 trial in essential thrombocythemia. The drug has shown rapid and sustained clinical responses, offering a new source of enthusiasm for Incyte as it prepares for additional data disclosures and a Phase 3 trial initiation. This development comes as the company faces a revenue gap due to the loss of exclusivity for Jakafi.

Signet Jewelers is undergoing a transformation under new leadership, with analyst Randal Konik initiating coverage with a Buy rating. The company’s Grow Brand Love strategy aims to streamline operations and enhance profitability, showing early signs of success with positive sales growth and increased social media engagement. Signet’s robust cash flow generation and attractive valuation make it a compelling investment opportunity as it continues its turnaround.

Wix has been upgraded to Buy by analyst Alec Brondolo, who expresses confidence in the company’s pricing strategy for 2026. Strong partner feedback and the potential for AI integration are expected to drive growth, with upcoming product releases serving as catalysts. Despite current trading challenges, Wix’s long-term prospects appear favorable, with the stock trading at a discount relative to its growth potential.